Wang et al used RT‐PCR method to detect CTCs in 221 BC patients, and CTC detection rate in each molecular subtype were 35/55 (63.6%) for luminal‐A, 19/27 (70.4%) for luminal‐B, 41/56 (73.2%) for luminal‐B HER2‐positive, 13/17 (76.5%) for HER2‐positive (nonluminal), and 24/31 (77.4%) for triple‐negative.32 Circulating tumor cell detection in Stage I‐IV BC patients are, respectively, 80.43%, 91.53%, 87.5%, and 100%. This evidence concerns the gene ERBB2 and breast cancer.